For a patient with sinus node dysfunction and intact AV conduction, is a leadless atrial‑only (AAI) pacemaker available, and what are the appropriate pacing options?

Leadless AAI Pacemakers: Current Availability and Pacing Options

Leadless atrial-only (AAI) pacemakers are now available and represent a significant advancement for patients with sinus node dysfunction and intact AV conduction, offering reduced complications compared to traditional transvenous systems. 1

Available Technology

The AVEIR AR leadless pacemaker is the first FDA-approved helix-fixation atrial leadless device specifically designed for AAI(R) pacing 1. This technology addresses the historical limitation of leadless pacing being restricted to ventricular chambers only.

Real-world data from 2024-2025 demonstrates that leadless atrial pacing with AVEIR AR shows:

• Lower 30-day complications compared to dual-chamber transvenous systems (6.7% vs 9.4%) 2
• Significantly fewer 1-year complications (3.6% vs 8.5% for dual-chamber transvenous) 2
• Reduced device reinterventions compared to both dual-chamber and right atrial transvenous systems 2
• Similar mortality rates to traditional pacing systems 2

Guideline-Based Pacing Recommendations

Primary Recommendation

For patients with sinus node dysfunction and intact AV conduction, dual-chamber (DDD) or single-chamber atrial (AAI) pacing is Class I recommended over ventricular pacing 3, 4. The 2012 HRS/ACCF consensus specifically states both modes are equally acceptable as first-line therapy.

When to Choose AAI Over DDD

AAI pacing may be considered (Class IIb) in selected patients with normal AV and ventricular conduction 3. The key selection criteria include:

1. Documented intact AV conduction on appropriate testing
2. Low risk of AV block progression (younger patients, no structural heart disease)
3. Absence of conduction abnormalities on ECG 4

Critical Risk Assessment: AV Block Progression

The annual incidence of new AV block in AAI-paced patients ranges from 0.6% to 4.4% across studies 5, 6. However:

• In younger populations (mean age ~55 years), the risk is minimal with 0% requiring device upgrade in some series 5
• In older populations, the DANPACE trial showed AAI pacing had a two-fold increased risk of pacemaker reoperation (HR 1.99) compared to dual-chamber systems 7
• 20% of patients with sinus node dysfunction have some degree of AV block at baseline 3

Practical Algorithm for Mode Selection

Choose Leadless AAI (AVEIR AR) When:

• Age <65 years with normal AV conduction
• No bundle branch block or PR prolongation
• No history of syncope suggesting intermittent AV block
• Patient preference for avoiding transvenous leads
• Vascular access limitations
• High infection risk (dialysis, immunosuppression)

Choose Dual-Chamber (DDD/DDDR) When:

• Age >65 years
• Any ECG evidence of conduction disease (PR >200ms, bundle branch block)
• History suggesting intermittent AV block
• Medications affecting AV conduction that cannot be discontinued
• Congenital heart disease with known AV node displacement 8, 9, 10

Programming Considerations for Dual-Chamber Systems

If dual-chamber is chosen, program to minimize ventricular pacing (Class IIa) to prevent atrial fibrillation 3. This is critical because:

• Unnecessary ventricular pacing increases AF risk
• Ventricular pacing can cause pacemaker-induced cardiomyopathy
• AV synchrony should be maintained through native conduction when possible

Clinical Outcomes: AAI vs DDD

AAI pacing demonstrates superior outcomes in properly selected patients:

• Lower hospitalization for heart failure: 0% vs 8.8% with DDD 6
• Reduced atrial fibrillation: 2.8% vs 15.2% with DDD 6
• Lower all-cause mortality compared to general population (SMR 0.89) 11
• Increased risk of atrial arrhythmias with DDD: HR 1.30 for new AF/flutter 11

Important Caveats

1. Rate-responsive pacing (AAIR) is reasonable (Class IIa) for patients with significant chronotropic incompetence 3, 4

2. Battery conservation is critical with leadless devices—program appropriately to maximize longevity 1

3. Do NOT use AAI/DDD in permanent atrial fibrillation (Class III)—this is an absolute contraindication 3

4. Technical expertise required: Leadless atrial implantation requires specific training in helix-fixation techniques and atrial anatomy 1

5. Follow-up monitoring: Patients with AAI require periodic assessment for development of AV block, though progression is rare in appropriately selected patients 5